Earnings Releases·Nov 12, 2026, 4:05 PM ET

BioStem Technologies — Third Quarter 2026 Earnings Summary

Net revenue declined 28% year-over-year to $7.6 million and 4% sequentially to $7.6 million, while GAAP net loss widened to $11.4 million ($0.64/share) from $9.0 million in the prior quarter; gross margin contracted to 56% from 61% sequentially due to higher BioTissue supply pricing.
Full-year 2026 revenue guidance was raised to $28–$29 million from $26–$29 million, and management targets a $10–$12 million reduction in annualized cash operating expenses starting Q1 2027 to narrow the adjusted EBITDA loss.
Liquidity remains constrained with cash and equivalents falling to $1.0 million from $7.0 million in Q2, though a $3 million private placement closed on September 30 and a $40 million committed equity facility was established, with sales potentially commencing in April 2027.
Strategic progress includes the integration of BioTissue logistics, the launch of a CRM/ERP system, and on-track in-house production of Neox® and Clarix® for H1 2027, while the company works to restructure a $10.0 million unpaid Clearance Payment to BioTissue.